A decade after critics first accused the Food and Drug Administration of downplaying side effects from Avandia, the agency says it will reveal on Friday the data it is reviewing ahead of an advisory panel meeting about the safety of the popular diabetes drug.
Should people who don't have high cholesterol take a cholesterol-lowering statin? Maybe, according to the U.S. Food and Drug Administration, which is considering an advisory panel's recent recommendation to do just that.
Taking a low-dose aspirin every day can help prevent heart attacks in people who've already had one. But if you've never had a heart attack (or stroke), the risks of taking a daily low-dose aspirin outweigh the benefits, according to a U.K. report published in Drug and Therapeutics Bulletin.
Healthy men and women with good cholesterol levels could significantly reduce their risk of heart disease by taking cholesterol-lowering drugs, better known as statins, according to a study released at the American Heart Association meetings in November.
As he walks the halls of the Cleveland Clinic, Dr. Steven Nissen makes the next generation of health care in America sound quite simple.
Actos and Avandia have entered the spotlight again, as studies published in a leading medical journal pit the two diabetes drugs against each other by comparing their cardiovascular risks.
Food and Drug Administration panelists voted Monday that GlaxoSmithKline's diabetes drug Avandia should remain on the market, despite an analysis showing links to increased risk of heart attack.
GlaxoSmithKline is getting ready for a face-to-face with the FDA about its diabetes drug Avandia, which has been on the hot seat since a study blamed the drug for increasing the risk of heart attack.
Merck's new drug Januvia controls blood-sugar in two-thirds of diabetics when combined with the drug metformin, the company said Saturday.
With concerns raised about heart risks of a popular diabetes drug, GlaxoSmithKline and the FDA scramble to respond
The moment of truth has come for Arcoxia, Merck's arthritis painkiller intended to replace the withdrawn drug Vioxx.
An extremely potent experimental cholesterol drug being developed by Eli Lilly and Co. failed to show an advantage over an existing treatment sold by Abbott Laboratories Inc. in a clinical trial that could determine the fate of the medicine.
It may be America's No. 1 killer, but people aren't scared enough of heart disease, says a top U.S. research cardiologist.
As Dr. Steven E. Nissen methodically ticks off the risks of what seemed like a highly promising experimental diabetes drug -- heart attacks, strokes, and death -- he is completely in his element.
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|